Rapport Therapeutics, Inc.
Rapport Therapeutics (Nasdaq: RAPP) is a clinical-stage biotechnology company developing small-molecule medicines for neurological and psychiatric disorders. Its RAP technology platform uses knowledge of receptor-associated proteins to identify drug targets and develop medicines designed to act on specific receptor… From the company’s description.
In fiscal 2025, Rapport Therapeutics, Inc. reported a net loss of $111.48M. Operations used $87.47M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rapport Therapeutics, Inc. does
In the company’s own words
Rapport Therapeutics (Nasdaq: RAPP) is a clinical-stage biotechnology company developing small-molecule medicines for neurological and psychiatric disorders. Its RAP technology platform uses knowledge of receptor-associated proteins to identify drug targets and develop medicines designed to act on specific receptor variants or brain regions. The lead candidate, RAP-219, is an AMPA receptor modulator targeting TARPγ8, and is being developed for focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Other programs include RAP-641, an α6β4 nicotinic acetylcholine receptor agonist in development for chronic pain and migraine, and discovery-stage α9α10 receptor modulators for hearing and vestibular disorders. Rapport operates as a single drug-discovery and development business, with programs spanning clinical development and earlier-stage research. Founded in 2022 with support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC, the company licensed certain TARPγ8 and nicotinic acetylcholine receptor assets from Janssen Pharmaceutical in 2022. Its website is https://rapporttherapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 2012593
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rapport Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rapport Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rapport Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rapport Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rapport Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”